THERAVECTYS
THERAVECTYS develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions..
Launch date
Employees
Market cap
-
Enterprise valuation
AUD112—168m (Dealroom.co estimates Feb 2021.)
Company register number 482324282
Paris Île-de-France (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenues | - | <1m | <1m | 3.5m | <1m | <1m |
| % growth | - | - | 93 % | 1224 % | (97 %) | (100 %) |
| EBITDA | (10.5m) | (2.2m) | (2.2m) | - | (3.5m) | (3.4m) |
| % EBITDA margin | - | (1634 %) | (831 %) | - | (3040 %) | (6093389 %) |
| Profit | (4.0m) | (3.0m) | (<1m) | <1m | (3.8m) | (3.2m) |
| % profit margin | - | (2172 %) | (378 %) | 15 % | (3284 %) | (5784295 %) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Spinout | |
€7.5m | Early VC | ||
| N/A | €14.7m | Late VC | |
€1.9m | Early VC | ||
* | N/A | €16.5m | Late VC |
| Total Funding | AUD69.0m | ||
Related Content
Recent News about THERAVECTYS
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.